147 related articles for article (PubMed ID: 8266611)
21. Urinary laminin-γ2 is a novel biomarker of non-muscle invasive urothelial carcinoma.
Kamada M; Koshikawa N; Minegishi T; Kawada C; Karashima T; Shuin T; Seiki M
Cancer Sci; 2015 Dec; 106(12):1730-7. PubMed ID: 26450632
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the NMP22 test and comparison with voided urine cytology in the detection of bladder cancer.
Lee KH
Yonsei Med J; 2001 Feb; 42(1):14-8. PubMed ID: 11293494
[TBL] [Abstract][Full Text] [Related]
23. Fluorescence in situ hybridization performed on exfoliated urothelial cells in patients with transitional cell carcinoma of the bladder.
Degtyar P; Neulander E; Zirkin H; Yusim I; Douvdevani A; Mermershtain W; Kaneti J; Manor E
Urology; 2004 Feb; 63(2):398-401. PubMed ID: 14972510
[TBL] [Abstract][Full Text] [Related]
24. Non-invasive molecular detection of bladder cancer recurrence.
Amira N; Mourah S; Rozet F; Teillac P; Fiet J; Aubin P; Cortesse A; Desgrandchamps F; Le Duc A; Cussenot O; Soliman H
Int J Cancer; 2002 Sep; 101(3):293-7. PubMed ID: 12209982
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic Efficiency of Serum and Urine Procathepsin B and Cathepsin B in Patients with Carcinoma of the Urinary Bladder.
Dusek P; Kotaska K; Vesely S; Prusa R; Babjuk M
Clin Lab; 2016 Sep; 62(9):1709-1715. PubMed ID: 28164592
[TBL] [Abstract][Full Text] [Related]
26. Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma.
Klein A; Zemer R; Buchumensky V; Klaper R; Nissenkorn I
Cancer; 1998 Jan; 82(2):349-54. PubMed ID: 9445193
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the UBC test in the urine of healthy individuals, patients with benign disorders and urinary bladder cancer.
Silén A; Rizvi SS; Letocha H; Lennernäs B; Wiklund B
Oncol Rep; 2000; 7(6):1269-74. PubMed ID: 11032928
[TBL] [Abstract][Full Text] [Related]
28. The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer.
Shariat SF; Casella R; Monoski MA; Sulser T; Gasser TC; Lerner SP
J Urol; 2003 Dec; 170(6 Pt 1):2244-7. PubMed ID: 14634389
[TBL] [Abstract][Full Text] [Related]
29. Detection of specific chromosomal aberrations in urine using BCA-1 (oligo-CGH-array) enhances diagnostic sensitivity and predicts the aggressiveness of non-muscle-invasive bladder transitional cell carcinoma.
Cussenot O; Sighar K; Mohammed M; Hugonin S; Ondet V; Larre S; Lacave R; Roupret M; Cancel-Tassin G
World J Urol; 2014 Apr; 32(2):551-7. PubMed ID: 24196429
[TBL] [Abstract][Full Text] [Related]
30. Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade.
Lokeshwar VB; Obek C; Pham HT; Wei D; Young MJ; Duncan RC; Soloway MS; Block NL
J Urol; 2000 Jan; 163(1):348-56. PubMed ID: 10604388
[TBL] [Abstract][Full Text] [Related]
31. Fetal fibronectin: a new screening-marker for bladder cancer?
Wunderlich H; Reichelt O; Zermann DH; Schubert J; Berndt A; Kosmehl H
Oncol Rep; 2001; 8(3):669-72. PubMed ID: 11295100
[TBL] [Abstract][Full Text] [Related]
32. Cathepsin B levels in urine from bladder cancer patients.
Eiján AM; Sandes E; Puricelli L; Bal De Kier Joffé E; Casabé AR
Oncol Rep; 2000; 7(6):1395-9. PubMed ID: 11032951
[TBL] [Abstract][Full Text] [Related]
33. Expression of CD147, BIGH3 and Stathmin and their potential role as diagnostic marker in patients with urothelial carcinoma of the bladder.
Bhagirath D; Abrol N; Khan R; Sharma M; Seth A; Sharma A
Clin Chim Acta; 2012 Oct; 413(19-20):1641-6. PubMed ID: 22626996
[TBL] [Abstract][Full Text] [Related]
34. Urinary biomarker profiling in transitional cell carcinoma.
Munro NP; Cairns DA; Clarke P; Rogers M; Stanley AJ; Barrett JH; Harnden P; Thompson D; Eardley I; Banks RE; Knowles MA
Int J Cancer; 2006 Dec; 119(11):2642-50. PubMed ID: 16991122
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the nuclear matrix protein 22 with voided urine cytology in the diagnosis of transitional cell carcinoma of the bladder.
Lekili M; Sener E; Demir MA; Temeltaş G; Müezzinoğlu T; Büyüksu C
Urol Res; 2004 May; 32(2):124-8. PubMed ID: 14685796
[TBL] [Abstract][Full Text] [Related]
36. Urinary cytokeratin 20 mRNA expression has the potential to predict recurrence in superficial transitional cell carcinoma of the bladder.
Christoph F; Weikert S; Wolff I; Schostak M; Tabiti K; Müller M; Miller K; Schrader M
Cancer Lett; 2007 Jan; 245(1-2):121-6. PubMed ID: 16473461
[TBL] [Abstract][Full Text] [Related]
37. [Non-invasive urine tests in diagnosis and as prognostic markers for urinary bladder carcinoma. Comparison of the BTAstat and NMP 22 tests with immunocytology using monoclonal antibodies against Lewis X and 486p3/12].
Friedrich MG; Hellstern A; Hautmann SH; Noldus I; Huland H
Urologe A; 2003 Apr; 42(4):523-30. PubMed ID: 12715124
[TBL] [Abstract][Full Text] [Related]
38. BTA-TRAK combined with urinary cytology is a reliable urinary indicator of recurrent transitional cell carcinoma (TCC) of the bladder.
Mattioli S; Seregni E; Caperna L; Botti C; Savelli G; Bombardieri E
Int J Biol Markers; 2000; 15(3):219-25. PubMed ID: 11012097
[TBL] [Abstract][Full Text] [Related]
39. CXCL5 is a potential diagnostic and prognostic marker for bladder cancer patients.
Zhu X; Qiao Y; Liu W; Wang W; Shen H; Lu Y; Hao G; Zheng J; Tian Y
Tumour Biol; 2016 Apr; 37(4):4569-77. PubMed ID: 26503215
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic value of voided urine and bladder barbotage cytology in detecting transitional cell carcinoma of the urinary tract.
Konety BR; Metro MJ; Melham MF; Salup RR
Urol Int; 1999; 62(1):26-30. PubMed ID: 10436427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
